» Articles » PMID: 25686833

Vacuolar ATPase 'a2' Isoform Exhibits Distinct Cell Surface Accumulation and Modulates Matrix Metalloproteinase Activity in Ovarian Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Feb 18
PMID 25686833
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor associated vacuolar H+-ATPases (V-ATPases) are multi-subunit proton pumps that acidify tumor microenvironment, thereby promoting tumor invasion. Subunit 'a' of its V0 domain is the major pH sensing unit that additionally controls sub-cellular targeting of V-ATPase and exists in four different isoforms. Our study reports an elevated expression of the V-ATPase-V0a2 isoform in ovarian cancer(OVCA) tissues and cell lines(A2780, SKOV-3 and TOV-112D). Among all V0'a' isoforms, V0a2 exhibited abundant expression on OVCA cell surface while normal ovarian epithelia did not. Sub-cellular distribution of V-ATPase-V0a2 confirmed its localization on plasma-membrane, where it was also co-associated with cortactin, an F-actin stabilizing protein at leading edges of cancer cells. Additionally, V0a2 was also localized in early and late endosomal compartments that are sites for modulations of several signaling pathways in cancer. Targeted inhibition of V-ATPase-V0a2 suppressed matrix metalloproteinase activity(MMP-9 & MMP-2) in OVCA cells. In conclusion, V-ATPase-V0a2 isoform is abundantly expressed on ovarian tumor cell surface in association with invasion assembly related proteins and plays critical role in tumor invasion by modulating the activity of matrix-degrading proteases. This study highlights for the first time, the importance of V-ATPase-V0a2 isoform as a distinct biomarker and possible therapeutic target for treatment of ovarian carcinoma.

Citing Articles

Monoclonal nanobodies alter the activity and assembly of the yeast vacuolar H-ATPase.

Knight K, Park J, Oot R, Khan M, Roh S, Wilkens S bioRxiv. 2025; .

PMID: 39829782 PMC: 11741422. DOI: 10.1101/2025.01.10.632502.


The role of ATP6V0D2 in breast cancer: associations with prognosis, immune characteristics, and TNBC progression.

Zhang J, Yang L, Xu B, Ji H, Liu S, Wang X Front Oncol. 2024; 14:1511810.

PMID: 39678496 PMC: 11638046. DOI: 10.3389/fonc.2024.1511810.


ATP6V1B1 regulates ovarian cancer progression and cisplatin sensitivity through the mTOR/autophagy pathway.

Mo S, Liu T, Zhou H, Huang J, Zhao L, Lu F Mol Cell Biochem. 2024; 480(2):1013-1026.

PMID: 38735913 PMC: 11835902. DOI: 10.1007/s11010-024-05025-w.


Identification of ATP6V0A4 as a potential biomarker in renal cell carcinoma using integrated bioinformatics analysis.

Xu J, Jiang J, Yin C, Wang Y, Shi B Oncol Lett. 2023; 26(3):366.

PMID: 37559594 PMC: 10407721. DOI: 10.3892/ol.2023.13952.


The cytosolic N-terminal domain of V-ATPase a-subunits is a regulatory hub targeted by multiple signals.

Tuli F, Kane P Front Mol Biosci. 2023; 10:1168680.

PMID: 37398550 PMC: 10313074. DOI: 10.3389/fmolb.2023.1168680.


References
1.
De Milito A, Fais S . Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2006; 1(6):779-86. DOI: 10.2217/14796694.1.6.779. View

2.
Sennoune S, Luo D, Martinez-Zaguilan R . Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys. 2004; 40(2):185-206. DOI: 10.1385/CBB:40:2:185. View

3.
Xu J, Xie R, Liu X, Wen G, Jin H, Yu Z . Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma. Carcinogenesis. 2012; 33(12):2432-40. DOI: 10.1093/carcin/bgs277. View

4.
Beaman K, Angkachatchai V, Gilman-Sachs A . TJ6: the pregnancy-associated cytokine. Am J Reprod Immunol. 1996; 35(4):338-41. DOI: 10.1111/j.1600-0897.1996.tb00490.x. View

5.
Rousselle A, Sihn G, Rotteveel M, Bader M . (Pro)renin receptor and V-ATPase: from Drosophila to humans. Clin Sci (Lond). 2014; 126(8):529-36. DOI: 10.1042/CS20130307. View